Comparative Pharmacology
Head-to-head clinical analysis: FLUOROURACIL versus PYQUVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOROURACIL versus PYQUVI.
FLUOROURACIL vs PYQUVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is metabolized to active nucleotides (FdUMP, FUTP) which incorporate into RNA and inhibit thymidylate synthase, leading to cell cycle arrest and apoptosis.
Pyquvi (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-2α, promoting erythropoietin production and iron mobilization, thereby stimulating erythropoiesis.
425 mg/m² IV bolus on days 1-5 every 28 days (Mayo regimen) or 400 mg/m² IV bolus on day 1, then 2400 mg/m² continuous IV infusion over 46 hours (FOLFOX regimen). For topical use, 5% cream applied twice daily for 2-4 weeks.
400 mg orally once daily with food, continued until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateFluorouracil + Digoxin
"Fluorouracil may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFluorouracil + Digitoxin
"Fluorouracil may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFluorouracil + Deslanoside
"Fluorouracil may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFluorouracil + Acetyldigitoxin
"Fluorouracil may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic: initial α-phase 10-20 min; terminal β-phase 16-20 min (no accumulation). For continuous infusion, functional half-life ~20 min. Clinically, rapid clearance necessitates infusion schedules.
The terminal elimination half-life is approximately 50 hours (range 40–60 hours), supporting once-daily dosing. Steady-state is achieved within 2–3 weeks of continuous dosing.
Renal: 60-80% as intact drug and metabolites (primarily urea, CO2, α-fluoro-β-alanine). Fecal: <10%. Biliary: minor.
Primarily hepatic metabolism via CYP3A4 and UGT1A9, with less than 5% of the dose excreted unchanged in urine. Fecal excretion accounts for approximately 70% of total clearance, primarily as metabolites.
Category D/X
Category C
Antimetabolite
Antimetabolite